// App-Quantinova.ai

: Immune Tolerance Induction with Simoctocog Alfa (Nuwiq®) in Six Patients with Severe Haemophilia a and FVIII Inhibitors

Researchers

Presenter

  • Neha Bhatnagar

Principal Investigators

  • Kate Khair

  • Ri Liesner

  • Alice Wilkinson

  • Larisa Belyanskaya

Medical Centers

  • Oxford Haemophilia and Thrombosis Comprehensive Care Centre, Children's Hospital Oxford, Oxford, United Kingdom

  • Great Ormond Street Hospital for Children, Haemophilia Comprehensive Care Centre, London, United Kingdom

  • Octapharma AG, Lachen, Switzerland

Locations

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • Alpha-1-microglobulin/bikunin precursor

Drug/Treatment

  • simoctocog alfa

  • Nuwiq

  • FVIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved